Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 436

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact

Open access
Cantini, Fabrizio, Niccoli, Laura, Matarrese, Daniela, Nicastri, Emanuele, Stobbione, Paolo, Goletti, Delia·2020·Journal of Infection

Abstract

•Baricitinib at 4 mg/day/orally was given to 12 patients with moderate COVID-19.•In baricitinib-treated patients no adverse events were recorded, after 2 weeks.•Clinical and respiratory parameters significantly improved at 2 weeks.•None of the baricitinib-treated patients required admission to ICU.•Proper control group was missing; this is required to demonstrate the efficacy. As discussed in the Journal recently1Li R. Qiao S. Zhang G Analysis of angiotensin-converting enzyme 2 (ACE2) from different species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV.J Infect. Apr 2020; 80: 469-496Scopus (103) Google Scholar the SARS-CoV-2, a new β-Coronavirus, uses the Angiotensin Converting Enzyme-2 Receptor to enter airway cells. Viral endocytosis is mediated by several factors, including clathrin, the adaptor protein-2 complex (AP2) and the adaptor-associated kinase-1 (AAK1).2Conner S.D. Schmid S.L Identification of an adaptor-associated kinase, AAK1, as a regulator of clathrin-mediated endocytosis.J Cell Biol. 2002; 156: 921-929Crossref PubMed Scopus (246) Google Scholar According to a recent report,3Huang C. Wang Y. Li X. et al.Clinical characteristics of patients infected with 2019 novel coronavirus in Wuhan, China.Lancet. 2020; 395: 497-506Abstract Full Text Full Text PDF PubMed Scopus (32456) Google Scholar COVID-19, the disease caused by SARS-CoV-2, is characterized by three clinical patterns: no symptoms, mild to moderate disease, severe pneumonia requiring admission to Intensive Care Unit (ICU) in up to 31% of the patients.3Huang C. Wang Y. Li X. et al.Clinical characteristics of patients infected with 2019 novel coronavirus in Wuhan, China.Lancet. 2020; 395: 497-506Abstract Full Text Full Text PDF PubMed Scopus (32456) Google Scholar Thus far, there is no specific therapy for COVID-19 infection. No benefit of lopinavir-ritonavir treatment resulted in a recent trial.4Cao B. Wang Y. Wen D. et al.A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.N Engl J Med. 2020 Mar 18; ([Epub ahead of print])https://doi.org/10.1056/NEJMoa2001282Crossref Scopus (3823) Google Scholar Hydroxychloroquine, currently used in view of its “in vitro” observed effect of reduction of viral replication, seems unsatisfactory.5Ferner R.E. Aronson J.K Chloroquine and hydroxychloroquine in covid-19.BMJ. 2020; 369: m1432https://doi.org/10.1136/bmj.m1432Crossref PubMed Scopus (280) Google Scholar Elevated proinflammatory cytokine/chemokine responses seem associated with respiratory failure.3Huang C. Wang Y. Li X. et al.Clinical characteristics of patients infected with 2019 novel coronavirus in Wuhan, China.Lancet. 2020; 395: 497-506Abstract Full Text Full Text PDF PubMed Scopus (32456) Google Scholar Recently, tocilizumab, an interleukin-6 inhibitor, was reported as effective in patients with severe COVID-19 pneumonia.6Xu X., Han M., Li T., et al. Effective treatment of severe COVID-19 patients with tocilizumab, 2020. ChinaXiv: 202003.00026v1.Google Scholar Baricitinib, another inhibitor of cytokine-release, seems an interesting anti-inflammatory drug. It is a Janus kinase inhibitor (anti-JAK) licensed for the treatment of rheumatoid arthritis (RA) with good efficacy and safety records.7Bechman K. Subesinghe S. Norton S. et al.A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis.Rheumatology. 2019; 58: 1755-1766Crossref PubMed Scopus (186) Google Scholar Moreover it seems to have anti-viral effects by its affinity for AP2-associated protein AAK1, reducing SARS-CoV-2 endocytosis.8Richardson P. Griffin I. Tucker C. et al.Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.Lancet. 2020; 395: e30-e31Abstract Full Text Full Text PDF PubMed Scopus (1064) Google Scholar On this basis, we assessed the safety of baricitinib therapy combined with lopinavir-ritonavir in moderate COVID-19 pneumonia patients and we evaluated its clinical impact. All consecutive hospitalized patients (March 16th −30th) with moderate COVID-19 pneumonia, older than 18 years, were treated for 2 weeks with baricitinib tablets 4 mg/day added to ritonavir-lopinavir therapy. The last consecutive patients with moderate COVID-19 pneumonia receiving standard of care therapy (lopinavir/ritonavir tablets 250 mg/bid and hydroxychloroquine 400 mg/day/orally for 2 weeks) admitted before the date of the first baricitinib-treated patient served as controls. Antibiotics were scheduled only in the case of suspected bacterial infection. Inclusion criteria were: a. SARS-Co-V2 positivity in the nasal/oral swabs; b. presence of at least 3 of the following symptoms: fever, cough, myalgia, fatigue; c. evidence of radiological pneumonia. After discharge, patients treated with baricitinib were planned to be followed for additional 6 weeks. Exclusion criteria: history of thrombophlebitis (TP), latent tuberculosis infection (QuantiFERON Plus-test positivity,

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jinf.2020.04.017

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 436

Metadata

Authors
Cantini, F., Niccoli, L., Matarrese, D., Nicastri, E., Stobbione, P., & Goletti, D.
Venue
Journal of Infection
Publisher
Elsevier BV
Published
2020-08
Volume
81
Issue
2
Pages
318-356
ISSN
0163-4453 (ISSN-L)
OpenAlex
W3017440151
Cited by
436
References
11
FWCI
12.37
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. https://app.cochat.ai/papers/10.1016/j.jinf.2020.04.017
The paper
Cantini, F., Niccoli, L., Matarrese, D., Nicastri, E., Stobbione, P., & Goletti, D. (2020). Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. Journal of Infection. https://doi.org/10.1016/j.jinf.2020.04.017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.